We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Social/economic costs and health-related quality of life in patients with scleroderma in Europe.
- Authors
López-Bastida, Julio; Linertová, Renata; Oliva-Moreno, Juan; Serrano-Aguilar, Pedro; Posada-de-la-Paz, Manuel; Kanavos, Panos; Taruscio, Domenica; Schieppati, Arrigo; Iskrov, Georgi; Péntek, Márta; Delgado, Claudia; Schulenburg, Johann; Persson, Ulf; Chevreul, Karine; Fattore, Giovanni; von der Schulenburg, Johann Mathias; BURQOL-RD Research Network
- Abstract
<bold>Objective: </bold>The aim of this study was to determine the economic burden from a societal perspective and the health-related quality of life (HRQOL) of patients with systemic sclerosis (SSc; scleroderma) in Europe.<bold>Methods: </bold>We conducted a cross-sectional study of patients with SSc (involving both localised and systemic sclerosis) from Germany, Italy, Spain, France, the UK, Hungary and Sweden. Data on demographic characteristics, healthcare resource utilisation, informal care, labour productivity losses and HRQOL were collected from the questionnaires completed by patients or their caregivers. HRQOL was measured with the EuroQol 5-domain (EQ-5D) questionnaire.<bold>Results: </bold>A total of 589 patients completed the questionnaire. The rate of patients with localised scleroderma, limited cutan and diffuse cutan SSc were 28, 68 and 4 %, respectively. Average annual costs varied from country to country and ranged from € 4607 to € 30,797 (reference year: 2012). Estimated direct healthcare costs ranged from € 1413 to € 17,300; direct non-healthcare costs ranged from € 1875 to € 4684 and labour productivity losses ranged from € 1701 to € 14,444. The mean EQ-5D index score for adult SSc patients varied from 0.49 to 0.75 and the mean EQ-5D visual analogue scale score was between 58.72 and 65.86.<bold>Conclusion: </bold>The main strengths of this study lie in our bottom-up approach to costing and our evaluation of SSs patients from a broad societal perspective. This type of analysis is very unusual in the international literature on rare diseases in comparison with other illnesses. We concluded that SSc patients incur considerable societal costs and experience substantial deterioration in HRQOL.
- Subjects
EUROPE; SYSTEMIC scleroderma; QUALITY of life; DEMOGRAPHIC characteristics; MEDICAL care costs; LABOR productivity; PATIENTS; MEDICAL economics; SICK leave; MEDICAL care cost statistics; CAREGIVERS; COMPARATIVE studies; ECONOMIC aspects of diseases; RESEARCH methodology; MEDICAL cooperation; QUESTIONNAIRES; RESEARCH; SICKNESS Impact Profile; SOCIOECONOMIC factors; EVALUATION research; VISUAL analog scale; ACQUISITION of data; CROSS-sectional method; PSYCHOLOGY; ECONOMICS
- Publication
European Journal of Health Economics, 2016, Vol 17, p109
- ISSN
1618-7598
- Publication type
journal article
- DOI
10.1007/s10198-016-0789-y